Oncolytics Biotech Inc. (ONCY) Q2 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to Oncolytics Biotech's second quarter 2024 conference call. All participants are now in a listen-only mode. There will be a question and answer session at the end of this call. Please be advised that this call is being recorded at the company's request. I would now like to turn the call over to Jan Patton, Director of Investor Relations and Communication. Please go ahead. Thank you, Operator. Earlier today, OnClinics issued a press release providing recent operational highlights and financial results for the second quarter of 2024. A replay of today's call will be available on the event section of the OnClinics website. And after remarks from company management, we will open the call for Q&A. As a reminder, various remarks made during this call contain certain forward-looking statements relating to the company's business prospects and the development and commercialization of Pella Reader App. including statements regarding the company's mission, strategy, and milestones, the company's belief as to the potential and mechanism of action of Pell Rear Up as a cancer therapeutic, our belief that we are positioned to execute on our key priorities and reach multiple milestones throughout the second half of the year and into 2025, our potential registrational opportunities for Pell Rear Up, anticipated timing of the release of additional data, our cash runway, and other statements related to anticipated developments in the company's business. These statements are based on management's current expectations and beliefs and are subject to a number of factors which involve known and unknown risks, delays, uncertainties, and other factors not under the company's control that may cause actual results, performance, or achievements of the company to be ma...